

## H. CLAIMS

What is claimed is:

- Sub B1 → 5
1. A method for the treatment of B cell lymphoma comprising the step of administering a therapeutically effective amount of at least one immunologically active, chimeric anti-CD20 antibody to a human.
  2. The method of claim 1 wherein the amount of said antibody administered to said human is between about 0.001 to about 30 milligrams of antibody per kilogram body weight of said human ("mg/kg").
  3. The method of claim 1 wherein said antibody is derived from a transfectoma comprising anti-CD20 in TCAE 8 as deposited with the American Type Culture Collection as part of ATCC deposit number 69119.
  - Sub B2 → 20  
4. The method of claim 1 further comprising the step of administering a second therapeutically effective amount of at least one immunologically active, chimeric anti-CD20 antibody.
  - 3  
5. The method of claim 4 wherein said additional administration of said antibody to said human occurs within about seven days of said first administration of said antibody to said human.
  - 25 6. A method for the treatment of B cell lymphoma comprising the steps of:
    - 1) administering, at a first administration period, a first therapeutically effective amount of immunologically active, chimeric anti-CD20 antibody to a human;
- 81  
-77-
- 82

2) administering at a second subsequent administration period, a second therapeutically effective amount of said antibody;

3) administering, at a third subsequent administration period, a third therapeutically effective amount of said antibody.

5

7. The method of claim 6 wherein said first, second and third therapeutically effective amount of said antibody is between about 0.001 mg/kg to about 30 mg/kg.

10 8. The method of claim 6 wherein said second administration period is within about seven days of said first administration period.

9. The method of claim 6 wherein said third administration period is within about fourteen days of said first administration period.

15

10. The method of claim 6 wherein said antibody is derived from a transfectoma comprising anti-CD20 in TCAE 8 (within ATCC deposit number 69119).

20 11. Immunologically active, chimeric anti-CD20 produced from a transfectoma comprising anti-CD20 in TCAE 8 (within ATCC deposit number 69119).

12. A hybridoma which secretes anti-CD20 antibody, said hybridoma being identified by American Type Culture Collection deposit number HB 11388.

25

13. A monoclonal antibody secreted from the hybridoma of claim 12.

14. A radiolabeled antibody according to claim 12.

15. The radiolabeled antibody of claim 14 where the radiolabel is selected from the group consisting of yttrium [90]; indium [111], and iodine [131].

5 16. A method for the treatment of B cell lymphoma comprising of steps of administering a therapeutically effective amount of the antibody of claim 14 to a human.

10 17. The method of claim 16 when the radiolabel of said antibody is yttrium [90].

18. A method for the treatment of B cell lymphoma comprising the steps of:

15 1) administering, at a first administration period, an immunology active chimeric anti-CD20 antibody to human; and

2) administering, at a second administration period, a radiolabeled anti-CD20 antibody to said human.

20 19. The method of claim 18 when said chimeric anti-CD20 is derived from a transfectoma comprising anti-CD20 in TCAE 8 as deposited with the American Type Culture Collection as part of ATCC deposit number 69119.

25 20. The method of claim 8 when said radiolabeled antibody comprises a monoclonal antibody secreted from a hybridoma identified by American Type Culture Collection deposit number HB 11388.

SL  
R17

add  
D17

add  
E17

83  
-78-